Nasdaq

Adverum Biotechnologies Introduces an Intravitreal Gene Therapy Program for Geographic Atrophy and Presents Data on Its Ocular Gene Therapy Platform

- Geographic atrophy (GA) program introduced with complement Factor I (CFI), a key component of the complement cascade, as a payload and utilizing two intravitreal (IVT) capsids, 7m8 and LSV1 - - IVT ...
Seeking Alpha

Adverum Biotechnologies Presents Anatomical Improvements in Intraretinal and Subretinal Fluid After a Single IVT Injection of Ixo-vec (ADVM-022) in the OPTIC Study in Wet AMD

- New data highlight that a single intravitreal injection of Ixo-vec can lead to stable and persistent aflibercept expression through three years resulting in fluid control supporting favorable vision ...
Business Insider

Graybug Vision Concludes Patient Enrollment in its Phase 2b Clinical Trial of GB-102 in Wet Age-Related Macular Degeneration and Accelerates Trial Read-out by Approximately Six ...

REDWOOD CITY, Calif., March 18, 2020 (GLOBE NEWSWIRE) -- Graybug Vision, Inc., a clinical stage biopharmaceutical company focused on developing transformative medicines to treat diseases of the retina ...
Business Wire

Genentech’s Susvimo Maintains Vision Over Five Years With Two Refills Per Year in People With Wet Age-Related Macular Degeneration (AMD)

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today new, five-year efficacy, safety and durability data from the Phase ...
Morningstar

Ashvattha Therapeutics to Present Positive Phase 2 Results for Subcutaneous Migaldendranib in Retinal Vascular Disease at ARVO

This approach targets the source of fluid leakage rather than the need for therapies that remove the fluid after an anti-VEGF injection in the eye. Subjects received a single anti-VEGF IVT and subQ ...